Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

An Open-Label Study of the Improvements in Clinical Symptoms and Neurocognitive Functions in Korean Children and Adolescents with Attention-Deficit Hyperactivity Disorder after Treatment with Metadate CD

국내 주의력결핍 과잉행동장애 아동 및 청소년에서 메타데이트CD의 임상증상 및 신경인지기능 개선 효과에 대한 개방 연구

  • Yoo, Han-Ik K. (Seoul Brain Research Institute) ;
  • Kim, Bong-Seog (Department of Psychiatry, Sanggye Paik Hospital, College of Medicine, Inje University) ;
  • Joung, Yoo-Sook (Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bahn, Geon-Ho (Department of Psychiatry, Kyung Hee University School of Medicine) ;
  • Song, Dong-Ho (Department of Child & Adolescent Psychiatry, Severance Children's Hospital and Institute for Behavioral Science in Medicine, Yonsei University College of Medicine) ;
  • Ahn, Dong-Hyun (Department of Psychiatry and Institute of Mental Health, Hanyang University College of Medicine) ;
  • Lee, Young-Sik (Department of Neuropsychiatry, Chung-Ang University College of Medicine)
  • 유한익 (서울뇌과학연구소) ;
  • 김봉석 (인제대학교 의과대학 상계백병원 정신과학교실) ;
  • 정유숙 (성균관대학교 의과대학 삼성서울병원 정신과학교실) ;
  • 반건호 (경희대학교 의학전문대학원 정신과학교실) ;
  • 송동호 (연세대학교 의과대학 의학행동과학연구소 및 세브란스 어린이병원 소아정신과학교실) ;
  • 안동현 (한양대학교 의과대학 정신과학교실 및 정신건강연구소) ;
  • 이영식 (중앙대학교 의과대학 중앙대학교병원 신경정신과학교실)
  • Received : 2011.03.22
  • Accepted : 2011.05.02
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neuro-cognitive functions. Methods : Ninety-one subjects with ADHD (mean age 8.6${\pm}$2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug's effects. Results : After 0.92${\pm}$0.32mg/kg/day of MCD were administered for 57.4${\pm}$7.6 days, there was a 48.5% reduction in the mean total ARS scores (p<.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p<.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p<.05). The forward memory span of the spatial working memory test scores increased (p<.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%). Conclusion : This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.

Keywords

References

  1. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59 Suppl 7:4-16.
  2. Brams M, Moon E, Pucci M, LOpez FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin 2010;26:1809-1825. https://doi.org/10.1185/03007995.2010.488553
  3. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-191. https://doi.org/10.3810/pgm.2010.01.2112
  4. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989;28:768-772. https://doi.org/10.1097/00004583-198909000-00020
  5. Pelham WE Jr, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491-501.
  6. Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39. https://doi.org/10.1542/peds.109.3.e39
  7. Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ. A postmarketing clinical experience study of Metadate CD. Curr Med Res Opin 2002; 18:371-380. https://doi.org/10.1185/030079902125001100
  8. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 2006;30: 1225-1245. https://doi.org/10.1016/j.neubiorev.2006.10.002
  9. Lee SH, Song DH, Kim BN, Joung YS, Ha EH, Cheon KA, et al. Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder. Yonsei Med J 2009;50:650-655. https://doi.org/10.3349/ymj.2009.50.5.650
  10. Song DH, Shin DW, Jon DI, Ha EH. Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test. Yonsei Med J 2005;46:34-41. https://doi.org/10.3349/ymj.2005.46.1.34
  11. Han DH, Lee YS, Na C, Ahn JY, Chung US, Daniels MA, et al. The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder. Compr Psychiatry 2009;50:251-256. https://doi.org/10.1016/j.comppsych.2008.08.011
  12. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009; 24:95-102. https://doi.org/10.1002/hup.1010
  13. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-216. https://doi.org/10.1016/j.pnpbp.2006.09.002
  14. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89. https://doi.org/10.3349/ymj.2004.45.1.81
  15. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: The Guilford Press;1998.
  16. Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 1985;21:809-843.
  17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Dept Health, Education, and Welfare publication;1976.
  18. Yoo HK, Lee J, Kang SH, Park EH, Jung J, Kim BN, et al. Standardization of the comprehensive attention test for the Korean children and adolescents. J Korean Acad Child Adolesc Psychiatry 2009;20: 68-75.
  19. Yoon HJ, Yook KH, Jon DI, Seok JH, Hong N, Cho SS, et al. Efficacy and tolerability of osmotic release oral system-methylphenidate in children with attention-deficit hyperactivity disorder according to comorbid psychiatric disorders. J Korean Acad Adolesc Psychiatry 2008;19:147-155.
  20. Kim B, Park E. An observational multi-center study for evaluation of efficacy, safety and parental satisraction of methylphenidate-OROS in children with ADHD. J Korean Acad Adolesc Psychiatry 2005;16:279-285.
  21. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657. https://doi.org/10.1097/01.chi.0000215326.51175.eb
  22. Anderson VR, Keating GM. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatr Drugs 2006;8:319-333. https://doi.org/10.2165/00148581-200608050-00005
  23. Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 2008;46:466-476. https://doi.org/10.5414/CPP46466
  24. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113:e206-e216. https://doi.org/10.1542/peds.113.3.e206
  25. Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002;41:443-449. https://doi.org/10.1097/00004583-200204000-00017
  26. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 2001;13:326-335. https://doi.org/10.1176/appi.neuropsych.13.3.326
  27. Nass RD. Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder. Semin Pediatr Neurol 2005; 12:200-216. https://doi.org/10.1016/j.spen.2005.12.002
  28. Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005;57:1424-1435. https://doi.org/10.1016/j.biopsych.2004.11.011
  29. Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:191-198. https://doi.org/10.1097/00004583-200402000-00015
  30. Trommer BL, Hoeppner JA, Zecker SG. The go-no go test in attention deficit disorder is sensitive to methylphenidate. J Child Neurol 1991;6 Suppl:S128-S131. https://doi.org/10.1177/088307389100600206
  31. Scheres A, Oosterlaan J, Swanson J, Morein-Zamir S, Meiran N, Schut H, et al. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. J Abnorm Child Psychol 2003;31:105-120. https://doi.org/10.1023/A:1021729501230
  32. Konrad K, GÜnther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B. Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial. J Child Adolesc Psychopharmacol 2005;15:180-190. https://doi.org/10.1089/cap.2005.15.180
  33. Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R. Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol 2003;31:315-127. https://doi.org/10.1023/A:1023285614844
  34. de Sonneville LM, Njiokiktjien C, Bos H. Methylphenidate and information processing. Part 1: Differentiation between responders and nonresponders; Part 2: Efficacy in responders. J Clin Exp Neuropsychol 1994;16:877-897. https://doi.org/10.1080/01688639408402700
  35. Hanisch C, Konrad K, Günther T, Herpertz-Dahlmann B. Age-dependent neuropsychological deficits and effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a comparison of pre- and grade-school children. J Neural Transm 2004;111:865-881.
  36. Fan J, McCandliss BD, Sommer T, Raz A, Posner MI. Testing the efficiency and independence of attentional networks. J Cogn Neurosci 2002;14:340-347. https://doi.org/10.1162/089892902317361886
  37. Raz A, Buhle J. Typologies of attentional networks. Nat Rev Neurosci 2006;7:367-379 https://doi.org/10.1038/nrn1903
  38. Jonkman LM, Kemner C, Verbaten MN, Van Engeland H, Kenemans JL, Camfferman G, et al. Perceptual and response interference in children with attention-deficit hyperactivity disorder, and the effects of methylphenidate. Psychophysiology 1999;36:419-429. https://doi.org/10.1111/1469-8986.3640419
  39. Ridderinkhof KR, Scheres A, Oosterlaan J, Sergeant JA. Delta plots in the study of individual differences: new tools reveal response inhibition deficits in AD/Hd that are eliminated by methylphenidate treatment. J Abnorm Psychol 2005;114:197-215. https://doi.org/10.1037/0021-843X.114.2.197
  40. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628. https://doi.org/10.1038/nrn896
  41. Bedard AC, Martinussen R, Ickowicz A, Tannock R. Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:260-268. https://doi.org/10.1097/00004583-200403000-00006
  42. Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 2004;45:293-305. https://doi.org/10.1111/j.1469-7610.2004.00221.x
  43. Rhodes SM, Coghill DR, Matthews K. Methylphenidate restores visual memory, but not working memory function in attention deficit- hyperkinetic disorder. Psychopharmacology (Berl) 2004;175:319-330 https://doi.org/10.1007/s00213-004-1833-7
  44. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994-1009.
  45. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010;157:635-640, 640.e1. https://doi.org/10.1016/j.jpeds.2010.04.025

Cited by

  1. An Open-Label Study of OROS-Methylphenidate for Neuropsychological Changes in Children and Adolescents with Attention-Deficit Hyperactivity Disorder vol.24, pp.3, 2013, https://doi.org/10.5765/jkacap.2013.24.3.157
  2. Augmentative Effects of Working Memory Training on Clinical Symptoms and Neuropsychology in Medicated Children and Adolescents with Attention-Deficit Hyperactivity Disorder vol.28, pp.2, 2017, https://doi.org/10.5765/jkacap.2017.28.2.123